Research Reports On Facebook (FB), Tesla (TSLA) & Others
Zacks Investment Research | Jul 21, 2016 02:01AM ET
Thursday, July 21, 2016
We have hand-picked 14 research reports in today's Research Daily write-up from the roughly 80 reports issued by our analysts team today. This includes the 6 research reports featured below about Johnson & Johnson (NYSE:JNJ) (JNJ), Citigroup (NYSE:C) (C), Facebook (NASDAQ:FB) (FB), Novartis (NVS), Tesla (NASDAQ:TSLA) (TSLA) and BHP Billiton (LON:BLT) (BHP).
Zacks Rank # 2 (Buy) rated Johnson & Johnson shares are up more than 20% year-to-date, with the momentum expected to continue to following the company's strong June quarter results. The analyst likes the company’s strategy of entering into several deals that hold the potential to boost its top line. The Cougar Biotechnology acquisition has allowed Johnson & Johnson to strengthen its oncology portfolio. A diversified business model, financial strength, new products and a deep pipeline are key elements of the JNJ story. (You can here .)
Citigroup shares have struggled this year, as have those of its peers, given the tough interest rate backdrop and uncertainty about the global ecnomic outlook. But the stock has got some of it mojo back following the better than expected second-quarter 2016 earnings report. The analyst likes the financial major’s capital strength, proven by the fact that it successfully cleared the 2016 Dodd-Frank Act Stress Test. A diverse business model, gradual offloading of non-core assets and streamlining of international businesses keep Citigroup's growth momentum alive. (You can here .)
Facebook has been riding high on its growing user and advertisers’ base along with its other offerings like Instagram, Oculus, Messenger and WhatsApp. Recently, Messenger crossed the 1 billion user milestone, joining the likes of Facebook and WhatsApp. The analyst is encouraged by higher online and mobile advertising spending on the social network, its strong user base and robust balance sheet. (You can here .)
Other noteworthy reports we are featuring today include Novartis (NVS), Tesla (TSLA) and BHP Billiton (BHP).
- .
Sheraz Mian
Director of Research
Note: Sheraz Mian regularly provides earnings analysis on Zacks.com and appears frequently in the print and electronic media. His weekly earnings related articles include portfolios.
If you want an email notification each time Sheraz publishes a new article, please .
Today's Must Read/h6
Featured Reports/h6
The Zacks analyst believes that growth from other drugs helped Novartis offset the loss from generic competition for Gleevec and beat both top and bottom-line estimates in the second quarter.
The covering analyst thinks McDonald's turnaround plan announced by CEO Steve Easterbrook in May 2015 and the sales initiatives are paying off and should aid in countering macroeconomic headwinds.
The Zacks analyst thinks Mondelez's organic sales trends have improved since 2015 backed by marketing support funded by cost savings.
St. Jude's expanding product portfolio, new product launches and frequent regulatory approvals are the key catalysts, according to the covering analyst.
The Master Plan will expand Tesla's product & services portfolio and diversify revenue sources.
The Zacks analyst thinks Silicon Motion will gain from surging demand for SSD controllers from NAND flash partners.
New Upgrades/h6
The covering analyst thinks BHP's Billiton growth prospects remain bright despite weak Q4 production results on the back of asset portfolio solidification, new innovations and manufacturing projects.
Waters Corp is riding high on strong pharmaceutical end markets, striking growth in recurring-revenue products and robust traction in China and India. These persistent trends look set to drive growth.
The Zacks analyst stresses that Stericycle's network is the largest in the industry and provides it with routing efficiencies for its vehicles to compete effectively on both service and price.
New Downgrades/h6
The Zacks analyst believes that the second quarter earnings underperformance would continue unless IMAX gets a successful blockbuster while expansion efforts could boost top-line.
The covering analyst thinks high interest expenses, surging medical care costs and the adverse effects of healthcare reform are likely to weigh on financials.
Get The News You Want
Read market moving news with a personalized feed of stocks you care about.Get The AppZacks Investment Research
Written By: Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.